Cryo-Cell International (NYSEAMERICAN:CCEL) Stock Passes Below 200-Day Moving Average – Should You Sell?

Shares of Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $3.45 and traded as low as $3.38. Cryo-Cell International shares last traded at $3.48, with a volume of 7,647 shares changing hands.

Cryo-Cell International Price Performance

The firm has a fifty day moving average of $3.52 and a 200 day moving average of $3.45. The stock has a market cap of $27.89 million, a price-to-earnings ratio of -11.53 and a beta of 0.49.

Cryo-Cell International (NYSEAMERICAN:CCEL) last issued its earnings results on Wednesday, July 15th. The company reported $0.07 earnings per share (EPS) for the quarter. The company had revenue of $7.78 million during the quarter.

Institutional Investors Weigh In On Cryo-Cell International

An institutional investor recently bought a new position in Cryo-Cell International stock. Susquehanna International Group LLP acquired a new position in shares of Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned about 0.14% of Cryo-Cell International at the end of the most recent quarter. 10.44% of the stock is currently owned by institutional investors and hedge funds.

About Cryo-Cell International

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.